BUSINESS

• Shareholders OK Nichi-Iko’s Delisting, Turnaround under New Management; President to Exit March 8
  February 20, 2023

• Healios Cuts 40 % of Employees Due to MultiStem Development Glitches
  February 17, 2023

• Nippon Shinyaku Grabs Japan Rights to Capricor’s DMD Cell Therapy
  February 17, 2023

• ViiV Eyes More Uptake for Japan’s 1st Long-Acting HIV Med, Revs Up Development Drive
  February 17, 2023

• As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
  February 15, 2023

• Mitsubishi Tanabe Wins Arbitration Case over Gilenya Royalty
  February 15, 2023

• Otsuka’s Pharma Sales Up 16.4% in 2022 on Global Brands, Hits 2023 Target 1 Year Earlier
  February 15, 2023

• Fujifilm Begins Japan PIII for Stem Cell Therapy in Meniscus Injuries
  February 15, 2023

• Mitsubishi Chemical Scraps Muse Cell Therapy Program
  February 15, 2023

• Sawai President Sounds Negative about M&As, but Agrees Generic Industry Needs Consolidation
  February 14, 2023

• Asahi Kasei Pharma Poised for a String of Approvals and Launch in 2023
  February 14, 2023

• Sawai President Declares Plan to Raise Shipment Prices in FY2023
  February 14, 2023

• Zeria to Take over Japan Marketing Authorization for Dafclir from Astellas
  February 14, 2023

• AbbVie Rolls Out Skyrizi Auto-Doser in Japan
  February 14, 2023

• Adcetris Filed for CTCL Indication in Japan: Takeda
  February 14, 2023

• BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
  February 14, 2023

• Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
  February 13, 2023

• Xocova’s Serious Side Effect Cases Total 5: Shionogi
  February 13, 2023

• Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
  February 10, 2023

• Fuji Pharma/M3’s Dysmenorrhea Drug Hits Main PIII Goal; 2024 Launch Eyed
  February 10, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 147
• 148
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• …
• Next ›
• 最終 »